N/A N=120 Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Community Acquired Pneumonia
Pneumonia
Primary: Use of Antibiotics in Each Group — 28; 52 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=670 Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia
Community-acquired Pneumonia · Bacterial Pneumonia
Primary: Percentage of Participants With Early Clinical Response at the Early Clinical Response (ECR) Visit — 89.6; 87.7; 8.6; 9.3 Percentage of participants
N/A N=66 Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Pneumonia and Pneumococcal Vaccine
Community Acquired Pneumonia
Primary: Use of Antibiotics in Each Group — 9; 21 participants — p=0.01
Phase 3 N=859 Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia
Community Acquired Bacterial Pneumonia
Primary: Early Clinical Response — 383; 381 Participants
N/A N=530 Clinical Characteristics and Microbiology of Healthcare Associated Pneumonia
Healthcare Associated Pneumonia
Primary: Pathogens of Healthcare Associated Pneumonia, Measured by the Number of Participants — 15; 51; 195; 269 Participants
Phase 3 N=738 Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia
Community Acquired Pneumonia
Primary: Early Clinical Response (ECR) — 336; 334; 29; 31 Participants
Phase 3 N=102 The Study Of Azithromycin Switch Therapy For Treatment Of Community Acquired Pneumonia (CAP)
Community Acquired Pneumonia (CAP)
Primary: Response Rate (Clinical Response, Data Review Committee Assessment) — 86.3; 84.5; 82.9 percentage of participants
Phase 4 N=49 Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus
Infections
Primary: Clinical Response at Study Day 4 in the Modified Intent-to-Treat (MITT) Population — 14; 8; 16; 8 participants
Phase 3 N=551 Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia
Community Acquired Pneumonia
Primary: Early Clinical Response (ECR) — 241; 248; 29; 21 Participants
Phase 4 N=385 Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children
Pneumonia
Primary: Desirability of Outcome Ranking (DOOR) — 97; 107; 47; 42 Participants — p=<0.001
Phase 3 N=584 Extended Steroid in Use in Community Acquired Pneumonia (CAP)(e)
Community Acquired Respiratory Disease Syndrome
Primary: 60-day Mortality — 50; 47; 227; 239 Participants — p=0.635
Phase 3 N=764 A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia
Community-Acquired Bacterial Pneumonia · Lung Infection of Individual Not Recently Hospitalized
Primary: Clinical Cure Rate for Ceftaroline Compared to That for Ceftriaxone at Test of Cure (TOC) in CE Population — 217; 178; 41; 62 Participants
N/A N=1,027 Improving CarE for Community Acquired Pneumonia 1
Pneumonia Childhood
Primary: Exclusive Guideline-Concordant Antibiotic Therapy, First 24 Hours — 255; 284; 174; 120 Participants
Phase 1 N=18 Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia
Community-acquired Pneumonia
Primary: Log Geometric Mean Area Under the Concentration Versus Time Curve (AUC) From Time 0 to 48 Hours After Dosing (AUC[0-48]) of Oral Omadacycline on Day 2 — 9.93 Hours x…
Early Phase 1 N=5 Procalcitonin to Reduce Antibiotic Use in Pediatric Pneumonia
Pneumonia · Pediatric Respiratory Diseases · Antibiotic Use
Primary: Total Pilot Trial Enrollment — 0; 1 Participants
Phase 3 N=521 Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia
Pneumonia
Primary: Clinical Cures in the Intent to Treat Population — 213; 224; 21; 9 Participants — p=0.0769
Phase 2 N=35 A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization
Pneumonia, Bacterial
Primary: Percentage of Participants With Clinical Response at Test of Cure (TOC) Visit — 90.0; 87.5; 62.5; 10.0 percentage of participants
Phase 2 N=158 Safety and Efficacy Study of Oxazolidinone to Treat Pneumonia
Community-Acquired Pneumonia (CAP)
Primary: Clinical Cure in the Clinically Evaluable (CE) Population at Test of Cure (TOC) — 34; 37; 32 Participants
Phase 4 N=12 Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia
Pneumonia, Bacterial · Community-acquired
Primary: Serum Cidal Activity as Tested Against Staphylococcus Aureus Isolates and Reported as Ex-vivo Effect (Log Inhibition of Growth) — 2; 4; 1; 1 Log inhibition
N/A N=20 Healthy Patients & Effect of Antibiotics
Microbiota · Anti-bacterial Agents
Primary: Degree of Microbial Disruption: Number of Patients With Recovery of Bacterial Species Richness at 185 Days Post-antibiotics — 3; 3; 2; 3 Participants
Phase 3 N=582 Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia (CAP)
Pneumonia
Primary: Clinical Cures in the Intent to Treat Population — 217; 206; 14; 13 Participants — p=0.5667
N/A N=536 Improving CarE for Community Acquired Pneumonia 1 (ICE-CAP2)
Pneumonia Childhood
Primary: Inappropriate Disposition — 7; 6 Participants
N/A N=127 Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly
Respiratory Disorders
Primary: Mean Estimated Number of Acute Exacerbation of COPD (AECOPD) — 3.04 AECOPD/subject/year
Phase 3 N=606 Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia
Bacterial Pneumonia
Primary: Clinical Cure Rate at Test-of-Cure (TOC) in the Modified Intent-to-Treat Efficacy (MITTE) Populations — 244; 233; 34; 58 participants
Phase 3 N=725 Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia
Pneumonia, Bacterial
Primary: Number of Participants Surviving Through LFU Visit — 191; 196; 64; 57 Participants — p=0.4263
Phase 3 N=138 Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia
Community-acquired Pneumonia (CAP) · Hospital-acquired Pneumonia (HAP)
Primary: Adverse Events — 10; 5; 1; 0 Participants
Phase 3 N=342 Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia
Pneumonia, Bacterial
Primary: Number of Patients With Clinical Success as Judged by the Investigator — 158; 145; 6; 8 Participants — p==0.499
Phase 3 N=774 Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
Bacterial Pneumonia · Community-Acquired Infections
Primary: Number of Participants With Early Clinical Response — 313; 321; 49; 47 Participants
Phase 2 N=158 Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia
Pseudomonas Aeruginosa Pneumonia
Primary: Clinical Cure on Day 21 — 34; 37; 6; 5 Participants — p=0.6154
Phase 3 N=537 Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)
Bacterial Pneumonia
Primary: Percentage of Participants With All-cause Mortality (ACM) Through Day 28 in the Modified Intention-to-treat (MITT) Population — 15.9; 21.3 Percentage of participants…